期刊文献+

血清胱抑素C检测对早期高血压肾病的临床价值 被引量:9

The importance of serum cystatin C in the early diagnosis of hypertensive nephropathy
下载PDF
导出
摘要 目的研究血清胱抑素C(CysC)在高血压肾病早期的诊断价值。方法对305例高血压患者组及330例健康对照组,均进行血清CysC、肌酐(CREA)、尿素氮(BUN)三项指标检测。CysC检测采用兔疫透射比浊法,CREA及BUN检测均采用酶法。结果高血压患者组血清CysC阳性率(55.1%)明显高于其血清CREA(38.7%)及BUN(42.3%)(P<0.01);轻度CysC增高患者组(A组)血清CysC阳性率与CREA、BUN比较皆有统计学意义(P<0.01),中、重度增高组(B、C组)血清CysC阳性率与CREA、BUN比较皆无统计学意义(P>0.05);1级高血压患者组血清CysC水平明显高于对照组(P<0.01),而血清CREA、BUN至2、3级才明显高于对照组。结论高血压肾病患者血清CysC的增高明显早于血清CREA和BUN,采用CysC对早期高血压肾病诊断比CREA、BUN敏感性更高、特异性更强,对高血压肾病的早期诊断有重要临床价值。 Objective To study the importance of serum cystatin (Cys)C in the early diagnosis of hypertensive ne-phropathy.Methods To test serum CysC-detected by immune transmission turbidity method,serum creatinine (CREA)and blood urea nitrogen (BUN)-determined by enzyme method,in patients with hypertension and healthy volunteers (n=305 and 330,respectively).Results The positive rate of serum CysC (55.1%)was significantly higher than that of serum CREA (8.7%)or BUN (42.3%)(P 〈0.01)in patients with hypertension.Patients with serum CysC slightly increased (group A)had higher serum CysC positive rate than that of serum CREA and BUN (P 〈0.01).There was no statistical significance (P 〉0.05)between serum CysC and CREA or BUN in patients with serum CysC moderately and severely increased (group B and C,respectively).Patients have grade 1 hypertendion had higher level of serum CysC than normal control (P 〈0.01),while only patients with grade 2 and 3 hypertension could be test-ed having higher CREA and BUN.Conclusion Serum CysC increases much earlier than CREA and BUN in patients with hypertension.It is more sensitive and special and has more marked clinic value using CysC to diagnose early-phase hypertensive.
作者 季广厚
出处 《中国实验诊断学》 2014年第6期985-987,共3页 Chinese Journal of Laboratory Diagnosis
关键词 肌抑素C 敏感性 特异性 高血压肾病 早期 cystatin C sensitivity specificity hypertensive nephropathy early phase
  • 相关文献

参考文献11

二级参考文献64

共引文献261

同被引文献50

  • 1李志玲,徐新伟,柴萍,李红艳,孙韶刚,吴良永.缬沙坦联合叶酸治疗老年高血压肾病的疗效研究[J].中国生化药物杂志,2014,34(4):123-125. 被引量:16
  • 2成威,周胜华,张铭,李旭平.阿托伐他汀对高血压肾病蛋白尿及C-反应蛋白和白介素-6的影响[J].高血压杂志,2005,13(12):767-770. 被引量:43
  • 3Schaeffer DF,Laiq 8,Jang HJ,et al.Abernethy malformation type II with nephrotic syndrome and other multisystemic presentation:An illustrative case for understanding pathogenesis of extrahepatic complication of congenital portosystemic shunt[J]. Human Pathology, 2015,44(3):432-437.
  • 4TaglieriN, KoeningW, KaskiJC.Cystatin -Candcaediovascnlarrisk [J].ClinChem, 2009,55 : 1932-1943.
  • 5PremaratneE Macl-saaoRJ, Finch S, etal.Serial measurement of cystatin-C are more accurate than creatinine-based methods in detecting decline renal function in type 1 diabetes[J].DiabetesCare 2008,31 : 971-973.
  • 6Russell F,King R,Smillie SJ,et al.Calcitonin generelated peptide:physiology and pathophysiology[J].Physiol Rev,2014,94(4):1099-1142.
  • 7Saraswat M,Addepalli V,Jain M,et al.Renoprotective activity of aliskiren,a renin inhibitor in cyclosporine A induced hypertensive nephropathy in dTG mice[J].Pharmacological Reports:PR,2014,66(1):62-67.
  • 8Nonaka K,Ubara Y,Sumida K,et al.Clinical and pathological evaluation of hypertensive emergency-related nephropathy[J].Internal Medicine,2013,52(1):45-53.
  • 9Baltatu O,Zaugg C,Schumacher C,et al.Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention[J].Pharmacological Research:The Official Journal of The Italian Pharmacological Society,2014,80:9-13.
  • 10Terawaki H,Nakayama M,Miyazawa E,et al.Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients:The Gonryo study[J].Clinical and Experimental Nephrology,2013,17(4):549-553.

引证文献9

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部